PTC THERAPEUTICS, INC.

Listed Company

PTCTCIK 0001070081NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.73B

Net Income

$682.64M

Total Assets

$2.90B

Equity

$-205.31M

Shares Out

8.29M

Op. Cash Flow

$711.20M

PTCT$83.34+69.66% · past yearDBEQ Basic

Daily closing prices

Business

PTC Therapeutics is a global biopharmaceutical company developing and commercializing clinically differentiated medicines for rare disorders affecting children and adults. The company offers commercial products including Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza/Kebilidi for aromatic L-amino acid decarboxylase deficiency, Evrysdi for spinal muscular atrophy, and Tegsedi and Waylivra for rare metabolic and neurological diseases. PTC operates through multiple geographic markets, including the United States, Europe, and Latin America, with a pipeline spanning splicing-modulation and inflammation/ferroptosis platforms targeting unmet neurological and metabolic needs.

Summary from 10-K filed 2026-02-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	1,731	807	938	699	539
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets	47	57	65	—	—
Amortization of acquired intangible assets	25	61	223	117	55
Research and development	455	534	667	651	541
Selling, general and administrative	347	301	333	326	286
Change in the fair value of contingent consideration	−800,000	−4	−128	−26	−500,000
Intangible asset impairment	—	160	218	33	—
Tangible asset impairment and (gains) losses on transactions, net	−10	750,000	—	—	—
Total operating expenses	864	1,109	1,377	1,146	913
Income (loss) from operations	867	−303	−440	−447	−374
Interest expense, net	−152	−167	−129	−91	−86
Other (expense) income, net	−18	7	10	−49	−58
Gain on sale of priority review voucher	—	100	—	—	—
Loss on extinguishment of debt	—	—	−138	—	—
Income (loss) before income tax (expense) benefit	697	−363	−696	−587	−518
Income tax (expense) benefit	−14	−176,000	70	28	−6
Net income (loss) attributable to common stockholders	683	−363	−627	−559	−524
Basic (in shares)	80	77	75	72	70
Diluted (in shares)	88	77	75	72	70
Basic	8.58	−4.73	−8.37	−7.79	−7.43
Diluted	7.78	−4.73	−8.37	−7.79	−7.43

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-03-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	985	—	780	594	280
Marketable securities	961	—	360	283	131
Trade and royalty receivables, net	182	—	159	161	156
Inventory, net	80	—	23	31	22
Prepaid expenses and other current assets	67	—	44	150	106
Total current assets	2,274	—	1,366	1,219	694
Fixed assets, net	55	—	61	87	73
Intangible assets, net	389	—	119	379	706
Goodwill	82	—	82	82	82
Operating lease ROU assets	80	—	57	92	102
Deposits and other assets	18	—	21	36	49
Total assets	2,899	—	1,705	1,896	1,706
Accounts payable and accrued expenses	381	—	304	392	320
Current portion of long-term debt	287	—	—	—	—
Deferred revenue	2	—	6	801,000	1
Operating lease liabilities- current	12	—	10	13	9
Finance lease liabilities- current	3	—	3	3	3
Liability for sale of future royalties- current	283	—	258	194	72
Total current liabilities	968	—	581	603	406
Long-term debt	—	—	285	284	572
Contingent consideration payable	—	0	800,000	36	164
Operating lease liabilities- noncurrent	94	—	75	98	101
Finance lease liabilities- noncurrent	3	—	16	17	19
Liability for sale of future royalties- noncurrent	2,025	—	1,824	1,620	686
Other long-term liabilities	14	—	21	141,000	3
Total liabilities	3,104	—	2,803	2,714	2,053
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025. Authorized 250,000,000 shares; issued and outstanding 77,704,188 shares at December 31, 2024.	80,000	—	77,000	75,000	72,000
Additional paid-in capital	2,748	—	2,575	2,466	2,305
Accumulated other comprehensive income (loss)	11	—	−26	−1	5
Accumulated deficit	−2,964	—	−3,647	−3,284	−2,657
Total stockholders' deficit	−205	—	−1,098	−819	−347
Total liabilities and stockholders' deficit	2,899	—	1,705	1,896	1,706

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	39	76	237	129	64
Non-cash operating lease expense	7	8	10	10	7
Non-cash royalty revenue related to sale of future royalties	−229	−182	−93	−49	−23
Non-cash interest expense on liability related to sale of future royalties	215	207	105	73	78
Change in valuation of contingent consideration	−800,000	−4	−128	−26	−500,000
Tangible asset impairment	1	4	—	—	—
Loss on sale of fixed assets	100,000	4	—	—	—
Gain on lease terminations	—	−2	—	—	—
Gain on lease modification	−11	−5	—	—	—
Unrealized (gain) loss on ClearPoint Equity Investments	−6	−8	2	4	6
Unrealized loss on ClearPoint convertible debt security	—	2	3	6	8
Realized loss on sale of ClearPoint Equity Investment	7	—	782,000	—	—
Realized loss on ClearPoint convertible debt security	—	622,000	—	—	—
Realized gain on sale of marketable securities - equity investments	—	—	−4	—	—
Unrealized gain on marketable securities - equity investments	−4	−3	−3	8	−2
Non-cash stock consideration, milestone payment	—	—	30	—	—
Disposal of asset	163,000	345,000	806,000	80,000	—
Deferred income taxes	−3,000	−56	−47	−34	377,000
Amortization of discounts on investments, net	−18	−13	−2	2	5
Amortization of debt issuance costs	1	1	2	2	2
Loss on extinguishment of debt	—	—	56	—	—
Share-based compensation expense	75	75	102	110	104
Unrealized foreign currency transaction losses (gains), net	3	−10	−14	13	47
Inventory, net	−54	6	−8	−7	2
Prepaid expenses and other current assets	−37	99	−45	−52	−15
Trade and royalty receivables, net	−10	2	−2	−48	−45
Deposits and other assets	3	12	5	−3	−232,000
Accounts payable and accrued expenses	72	−33	48	28	46
Other liabilities	−17	12	−2	−5	−7
Deferred revenue	−4	5	−550,000	1	−4
Payments on contingent consideration	−5	−2	—	−10	—
Net cash provided by (used in) operating activities	711	−108	−158	−357	−251
Purchases of fixed assets	−9	−7	−28	−32	−28
Proceeds from sale of fixed assets	70,000	28	—	—	—
Proceeds from sale of priority review voucher	—	150	—	—	—
Purchases of marketable securities- available for sale	−1,364	−608	−174	−53	−333
Purchases of marketable securities- equity investments	−54	−59	−38	−23	−210
Sale of marketable securities- available for sale	784	550	22	405	843
Sale of marketable securities- equity investments	59	48	132	113	4
Sale of ClearPoint Equity Investments	12	—	3	—	—
Proceeds from settlement of Clearpoint convertible debt security	—	10	—	—	—
Acquisition of product rights and licenses	−291	−68	−92	−120	−57
Net cash (used in) provided by investing activities	−862	44	−177	290	219
Proceeds from exercise of options	93	29	24	15	17
Proceeds from employee stock purchase plan	6	5	6	6	6
Repayment of senior secured term loan	—	—	−300	—	—
Debt extinguishment costs related to senior secured term loan	—	—	−82	—	—
Cash consideration received from A&R Royalty Purchase Agreement	240	242	1,000	—	—
Debt issuance costs related to senior secured term loan	—	—	−282,000	−11	—
Payments on contingent consideration obligation	−6	−18	—	−40	—
Payment of finance lease principal	−2	−1	−1	−1	−2
Net cash provided by financing activities	331	256	646	168	21
Effect of exchange rate changes on cash	23	−7	3	−3	−8
Net increase in cash and cash equivalents	203	185	314	99	−19
Cash paid for interest	6	6	36	18	10
Federal	27	—	—	—	—
Total income taxes paid, net of refunds recieved	37	18	14	5	8
Right-of-use assets obtained in exchange for operating lease obligations	28	6	—	36	645,000
Acquisition of product rights and licenses	1	420,000	55	33	22
Fixed asset additions through tenant improvement allowance	766,000	19	—	—	—
Capital expenditures unpaid at the end of period	126,000	70,000	—	308,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is PTC THERAPEUTICS, INC.'s CIK number?

PTC THERAPEUTICS, INC.'s SEC CIK number is 0001070081 (1070081). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find PTC THERAPEUTICS, INC.'s SEC filings?

All of PTC THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did PTC THERAPEUTICS, INC. last report earnings?

PTC THERAPEUTICS, INC. (PTCT) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001070081-26-000011). This is PTC THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is PTC THERAPEUTICS, INC.'s most recent earnings 8-K?

PTC THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001070081-26-000011. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View PTC THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →